FTC and seven states seek contempt ruling against Shkreli over pharma ban
Martin Shkreli’s 2022 release conditions bar him from participating in the pharmaceutical industry, including ownership stakes or business decisions The Federal Trade Commission (FTC) and seven US states have alleged that pharmaceutical executive Martin Shkreli repeatedly violated a lifetime ban on participating in the pharmaceutical industry, and they are asking a judge to hold him in contempt. In a motion filed…
Resumo da notícia
Martin Shkreli’s 2022 release conditions bar him from participating in the pharmaceutical industry, including ownership stakes or business decisions The Federal Trade Commission (FTC) and seven US states have alleged that pharmaceutical executive Martin Shkreli repeatedly violated a lifetime ban on participating in the pharmaceutical industry, and they are asking a judge to hold him in contempt. In a motion filed…
Acompanhe as notícias de fontes confiáveis com resumos breves. Abra o link original para ver os detalhes.